Literature DB >> 28293832

The Mechanistic Role of the Calcium-Activated Chloride Channel ANO1 in Tumor Growth and Signaling.

Anke Bill1, Larry Alex Gaither2.   

Abstract

Multiple studies have described the high expression and amplification of Anoctamin 1 (ANO1) in various cancers, including, but not limited to breast cancer, head and neck cancer, gastrointestinal stromal tumors and glioblastoma. ANO1 has been demonstrated to be critical for tumor growth in breast and head and neck cancers through its regulation of EGFR signaling and pathway modulators like MAPK and protein kinase B. However, the discovery of ANO1 as a calcium activated chloride channel came as a surprise to the field and has given rise to many questions. How does a chloride channel promote oncogenesis? Is the chloride channel function of ANO1 important for its role in cancer? Does ANO1 exhibits chloride-independent functions in cancer cells? This review summarizes the current understanding of ANO1's function in cancer, provides a synopsis of the findings addressing the open questions in the field and gives an outlook on the promising future of ANO1 as a potential therapeutic target for the treatment of various cancers.

Entities:  

Keywords:  Anoctamin 1; Cancer; Chloride Channel; High-Throughput Mutagenesis; Variomics

Mesh:

Substances:

Year:  2017        PMID: 28293832     DOI: 10.1007/5584_2016_201

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  11 in total

1.  TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis.

Authors:  David Crottès; Yu-Hsiu T Lin; Christian J Peters; John M Gilchrist; Arun P Wiita; Yuh Nung Jan; Lily Yeh Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

2.  A network of phosphatidylinositol 4,5-bisphosphate binding sites regulates gating of the Ca2+-activated Cl- channel ANO1 (TMEM16A).

Authors:  Kuai Yu; Tao Jiang; YuanYuan Cui; Emad Tajkhorshid; H Criss Hartzell
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-12       Impact factor: 11.205

Review 3.  Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.

Authors:  Nagore Del-Río-Ibisate; Rocío Granda-Díaz; Juan P Rodrigo; Sofía T Menéndez; Juana M García-Pedrero
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 4.  TMEM16A as a potential treatment target for head and neck cancer.

Authors:  Kohei Okuyama; Souichi Yanamoto
Journal:  J Exp Clin Cancer Res       Date:  2022-06-07

Review 5.  Using human genetics to improve safety assessment of therapeutics.

Authors:  Keren J Carss; Aimee M Deaton; Alberto Del Rio-Espinola; Dorothée Diogo; Mark Fielden; Diptee A Kulkarni; Jonathan Moggs; Peter Newham; Matthew R Nelson; Frank D Sistare; Lucas D Ward; Jing Yuan
Journal:  Nat Rev Drug Discov       Date:  2022-10-19       Impact factor: 112.288

Review 6.  Calcium-Activated Chloride Channel ANO1/TMEM16A: Regulation of Expression and Signaling.

Authors:  Nickolai O Dulin
Journal:  Front Physiol       Date:  2020-11-05       Impact factor: 4.566

7.  Prognostic significance of ANO1 expression in cancers.

Authors:  Congxiao Zhang; Haini Li; Jing Gao; Xiaoqing Cui; Shengmei Yang; Zongtao Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

Review 8.  Molecular mechanisms of activation and regulation of ANO1-Encoded Ca2+-Activated Cl- channels.

Authors:  M B Hawn; E Akin; H C Hartzell; I A Greenwood; N Leblanc
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

Review 9.  TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?

Authors:  Henry Danahay; Martin Gosling
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

10.  Integrated analysis of genomic and transcriptomic profiles identified a prognostic immunohistochemistry panel for esophageal squamous cell cancer.

Authors:  Yue Yu; Zhihua Li; Chenjun Huang; Haisheng Fang; Fei Zhao; Yue Zhou; Xianglong Pan; Qifan Li; Yu Zhuang; Liang Chen; Jing Xu; Wei Wang
Journal:  Cancer Med       Date:  2019-12-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.